Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data

Background: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, but evidence for their eff ectiveness in reducing mortality is uncertain. We did a meta-analysis of individual participant data to investigate the association between use of neuraminidase inhibitors a...

Ամբողջական նկարագրություն

Մատենագիտական մանրամասներ
Հիմնական հեղինակներ: Muthuri, S, Venkatesan, S, Myles, P, Leonardi-Bee, J, Al Khuwaitir, T, Al Mamun, A, Anovadiya, A, Azziz-Baumgartner, E, Báez, C, Bassetti, M, Beovic, B, Bertisch, B, Bonmarin, I, Booy, R, Borja-Aburto, V, Burgmann, H, Cao, B, Carratala, J, Denholm, J, Dominguez, SR, Duarte, P, Dubnov-Raz, G, Echavarria, M, Fanella, S, Gao, Z
Ձևաչափ: Journal article
Լեզու:English
Հրապարակվել է: 2014
_version_ 1826275220965556224
author Muthuri, S
Venkatesan, S
Myles, P
Leonardi-Bee, J
Al Khuwaitir, T
Al Mamun, A
Anovadiya, A
Azziz-Baumgartner, E
Báez, C
Bassetti, M
Beovic, B
Bertisch, B
Bonmarin, I
Booy, R
Borja-Aburto, V
Burgmann, H
Cao, B
Carratala, J
Denholm, J
Dominguez, SR
Duarte, P
Dubnov-Raz, G
Echavarria, M
Fanella, S
Gao, Z
author_facet Muthuri, S
Venkatesan, S
Myles, P
Leonardi-Bee, J
Al Khuwaitir, T
Al Mamun, A
Anovadiya, A
Azziz-Baumgartner, E
Báez, C
Bassetti, M
Beovic, B
Bertisch, B
Bonmarin, I
Booy, R
Borja-Aburto, V
Burgmann, H
Cao, B
Carratala, J
Denholm, J
Dominguez, SR
Duarte, P
Dubnov-Raz, G
Echavarria, M
Fanella, S
Gao, Z
author_sort Muthuri, S
collection OXFORD
description Background: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, but evidence for their eff ectiveness in reducing mortality is uncertain. We did a meta-analysis of individual participant data to investigate the association between use of neuraminidase inhibitors and mortality in patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection. Methods: We assembled data for patients (all ages) admitted to hospital worldwide with laboratory confi rmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection. We identifi ed potential data contributors from an earlier systematic review of reported studies addressing the same research question. In our systematic review, eligible studies were done between March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 2010); however, we continued to receive data up to March 14, 2011, from ongoing studies. We did a meta-analysis of individual participant data to assess the association between neuraminidase inhibitor treatment and mortality (primary outcome), adjusting for both treatment propensity and potential confounders, using generalised linear mixed modelling. We assessed the association with time to treatment using time-dependent Cox regression shared frailty modelling. Findings: We included data for 29 234 patients from 78 studies of patients admitted to hospital between Jan 2, 2009, and March 14, 2011. Compared with no treatment, neuraminidase inhibitor treatment (irrespective of timing) was associated with a reduction in mortality risk (adjusted odds ratio [OR] 0.81; 95% CI 0.70-0.93; p=0.0024). Compared with later treatment, early treatment (within 2 days of symptom onset) was associated with a reduction in mortality risk (adjusted OR 0.48; 95% CI 0.41-0.56; p<0.0001). Early treatment versus no treatment was also associated with a reduction in mortality (adjusted OR 0.50; 95% CI 0.37-0.67; p<0.0001). These associations with reduced mortality risk were less pronounced and not signifi cant in children. There was an increase in the mortality hazard rate with each day's delay in initiation of treatment up to day 5 as compared with treatment initiated within 2 days of symptom onset (adjusted hazard ratio [HR 1.23] [95% CI 1.18-1.28]; p<0.0001 for the increasing HR with each day's delay). Interpretation We advocate early instigation of neuraminidase inhibitor treatment in adults admitted to hospital with suspected or proven influenza infection.
first_indexed 2024-03-06T22:55:24Z
format Journal article
id oxford-uuid:6031429b-667c-4ce0-8b54-e4b2e42cdbcd
institution University of Oxford
language English
last_indexed 2024-03-06T22:55:24Z
publishDate 2014
record_format dspace
spelling oxford-uuid:6031429b-667c-4ce0-8b54-e4b2e42cdbcd2022-03-26T17:52:24ZEffectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant dataJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6031429b-667c-4ce0-8b54-e4b2e42cdbcdEnglishSymplectic Elements at Oxford2014Muthuri, SVenkatesan, SMyles, PLeonardi-Bee, JAl Khuwaitir, TAl Mamun, AAnovadiya, AAzziz-Baumgartner, EBáez, CBassetti, MBeovic, BBertisch, BBonmarin, IBooy, RBorja-Aburto, VBurgmann, HCao, BCarratala, JDenholm, JDominguez, SRDuarte, PDubnov-Raz, GEchavarria, MFanella, SGao, ZBackground: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, but evidence for their eff ectiveness in reducing mortality is uncertain. We did a meta-analysis of individual participant data to investigate the association between use of neuraminidase inhibitors and mortality in patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection. Methods: We assembled data for patients (all ages) admitted to hospital worldwide with laboratory confi rmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection. We identifi ed potential data contributors from an earlier systematic review of reported studies addressing the same research question. In our systematic review, eligible studies were done between March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 2010); however, we continued to receive data up to March 14, 2011, from ongoing studies. We did a meta-analysis of individual participant data to assess the association between neuraminidase inhibitor treatment and mortality (primary outcome), adjusting for both treatment propensity and potential confounders, using generalised linear mixed modelling. We assessed the association with time to treatment using time-dependent Cox regression shared frailty modelling. Findings: We included data for 29 234 patients from 78 studies of patients admitted to hospital between Jan 2, 2009, and March 14, 2011. Compared with no treatment, neuraminidase inhibitor treatment (irrespective of timing) was associated with a reduction in mortality risk (adjusted odds ratio [OR] 0.81; 95% CI 0.70-0.93; p=0.0024). Compared with later treatment, early treatment (within 2 days of symptom onset) was associated with a reduction in mortality risk (adjusted OR 0.48; 95% CI 0.41-0.56; p<0.0001). Early treatment versus no treatment was also associated with a reduction in mortality (adjusted OR 0.50; 95% CI 0.37-0.67; p<0.0001). These associations with reduced mortality risk were less pronounced and not signifi cant in children. There was an increase in the mortality hazard rate with each day's delay in initiation of treatment up to day 5 as compared with treatment initiated within 2 days of symptom onset (adjusted hazard ratio [HR 1.23] [95% CI 1.18-1.28]; p<0.0001 for the increasing HR with each day's delay). Interpretation We advocate early instigation of neuraminidase inhibitor treatment in adults admitted to hospital with suspected or proven influenza infection.
spellingShingle Muthuri, S
Venkatesan, S
Myles, P
Leonardi-Bee, J
Al Khuwaitir, T
Al Mamun, A
Anovadiya, A
Azziz-Baumgartner, E
Báez, C
Bassetti, M
Beovic, B
Bertisch, B
Bonmarin, I
Booy, R
Borja-Aburto, V
Burgmann, H
Cao, B
Carratala, J
Denholm, J
Dominguez, SR
Duarte, P
Dubnov-Raz, G
Echavarria, M
Fanella, S
Gao, Z
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data
title Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data
title_full Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data
title_fullStr Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data
title_full_unstemmed Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data
title_short Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data
title_sort effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza a h1n1pdm09 virus infection a meta analysis of individual participant data
work_keys_str_mv AT muthuris effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT venkatesans effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT mylesp effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT leonardibeej effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT alkhuwaitirt effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT almamuna effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT anovadiyaa effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT azzizbaumgartnere effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT baezc effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT bassettim effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT beovicb effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT bertischb effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT bonmarini effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT booyr effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT borjaaburtov effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT burgmannh effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT caob effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT carratalaj effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT denholmj effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT dominguezsr effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT duartep effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT dubnovrazg effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT echavarriam effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT fanellas effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata
AT gaoz effectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaah1n1pdm09virusinfectionametaanalysisofindividualparticipantdata